Health Catalyst 10-Q: $40.5M Q3 Profit on Vitalware Gain, $122.5M Impairment, Debt Wiped Out
HCAT sits 57% above its 52-week low of $0.955.
Summary
Health Catalyst's Q3 10-Q shows a $40.5 million profit driven by the $65.9 million Vitalware sale gain, a $122.5 million nine-month goodwill impairment, and a debt-free balance sheet with $79.0 million in cash after repaying its credit agreement.
Key Events · Earnings and Guidance · HCAT
-
Q3 Profit Driven by Divestiture Gain
Net income of $40.5 million ($0.53 diluted) versus a $22.2 million loss a year ago, almost entirely from a $65.9 million pre-tax gain on the Vitalware sale.
-
Revenue Falls 26% as Core Shrinks
Total revenue dropped to $56.3 million from $76.3 million, with technology down 22% and professional services down 36%; Adjusted EBITDA fell to $0.8 million from $12.0 million.
-
Goodwill Impairment Hits $122.5M
Nine-month non-cash goodwill impairment of $122.5 million to the technology reporting unit, driven by the stock price and market cap decline plus the Vitalware held-for-sale accounting.
-
Debt Fully Repaid and Terminated
Used $144.5 million of net Vitalware proceeds plus cash to repay all Credit Agreement obligations on July 31, 2026, booking a $9.5 million loss on extinguishment; no debt remains.
Analysis · HCAT · Technology
The headline numbers were already out via this morning's earnings release, but the full 10-Q fills in what actually drove them. The $40.5 million quarterly profit is almost entirely a $65.9 million pre-tax gain on selling Vitalware, not operating improvement — revenue fell 26% to $56.3 million and Adjusted EBITDA collapsed to $0.8 million from $12.0 million. Against that, the company took a $122.5 million non-cash goodwill impairment over nine months as its market value fell, and used the $144.5 million of net Vitalware proceeds to repay and terminate its entire credit agreement, booking a $9.5 million extinguishment loss. The balance sheet is now debt-free with $79.0 million of cash and investments, which buys runway but removes the high-margin Vitalware business that was propping up profitability.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCAT was trading at $1.50 on NASDAQ in the Technology sector, with a market capitalization of approximately $112.9M. The 52-week trading range was $0.96 to $3.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.